Importantly, when gated on CD69+CD49a+ or CD69+CD103+ cells, DFMO cotreatment led to increased levels of IFN-γ and TNF-α in post–rapid expansion protocol (post-REP) human sarcoma TIL (Supplemental Figure 5, A and B). Here, CD69 is linked to sarcoma.